Clinical trial
Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial…
NCT00005025 · John Stoddard Cancer Center at Iowa Methodist Medical Center, Other · Unknown status
Key facts
| NCT number | NCT00005025 |
|---|---|
| Title | Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer |
| Official title | A Phase II Trial of In Vivo Gene Therapy With the Herpes Simplex Thymidine Kinase for the Treatment of Ovarian Cancer |
| Lead sponsor | John Stoddard Cancer Center at Iowa Methodist Medical Center, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer |
| Intervention type | Biological, Drug |
| Interventions | herpes simplex thymidine kinase, ganciclovir |
| Start date | Jun 1, 2000 |
| First posted | May 5, 2003 |
| Last update posted | Nov 6, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: